



NDA 022101/ S-008
NDA 021153/S-040
NDA 021957/S-011

SUPPLEMENT APPROVAL

AstraZeneca LP
Attention: Judy W. Firor
Director, Regulatory Affairs
1800 Concord Pike PO Box 8355
Wilmington, DE 19803-8355

Dear Ms. Firor:

Please refer to your Supplemental New Drug Applications (sNDAs) dated and received July 28, 2011, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Nexium (esomeprazole magnesium) Delayed-Release Capsules, 20 mg and 40 mg; For Delayed-Release Oral Suspension, 10 mg, 20 mg, and 40 mg.

We acknowledge receipt of your amendments dated December 1, 2011 and January 12 & 17, 2012.

These Prior Approval supplemental new drug applications provides for the following:

- Addition of microscopic colitis to post-marketing experience
- Addition of erlotinib to Drug Interactions section
- Addition of concomitant use of methotrexate with Proton Pump Inhibitors to the Warnings and Precautions and Drug Interactions section

We have completed our review of these supplemental applications, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(1)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>. Content of labeling must be identical to the enclosed labeling (text for the package insert and the patient package insert), with the addition of any labeling changes in pending "Changes Being Effectuated" (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eLIST may be found in the guidance for industry titled “SPL Standard for Content of Labeling Technical Qs and As” at <http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf>.

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in MS Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes and annotate each change. To facilitate review of your submission, provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

All promotional materials that include representations about your drug product must be promptly revised to be consistent with the labeling changes approved in this supplement, including any new safety information [21 CFR 314.70(a)(4)]. The revisions in your promotional materials should include prominent disclosure of the important new safety information that appears in the revised package labeling. Within 7 days of receipt of this letter, submit your statement of intent to comply with 21 CFR 314.70(a)(4) to the address above or by fax to 301-847-8444.

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Stacy Barley, Regulatory Project Manager, at (301) 796-2137.

Sincerely,

{See appended electronic signature page}

Joyce Korvick, M.D., M.P.H.
Deputy Director for Safety
Division of Gastroenterology and Inborn Errors
Products
Office of Drug Evaluation III
Center for Drug Evaluation and Research

ENCLOSURE: Content of Labeling

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

JOYCE A KORVICK
01/20/2012